Login / Signup

Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies.

Helena Freire HaddadJacqueline A BurkeEvan A ScottGuillermo A Ameer
Published in: Regenerative engineering and translational medicine (2021)
Poly(ethylene glycol) (PEG) is a polymer found in products including cosmetics, personal care products, cleaning agents, medicine, and food. Due to the prevalence of PEG, people can develop antibodies (αPEG Abs) against the polymer, which recognize PEG as foreign. Of note, PEG is frequently incorporated into drug formulations to improve therapeutic efficacy. Complications can arise when a patient receiving a PEGylated drug has previously developed αPEG Abs from interactions with PEG in everyday products. The presence of high concentrations of αPEG Abs in blood can result in decreased treatment efficacy and allergic reactions to a wide range of therapeutics.
Keyphrases
  • drug delivery
  • healthcare
  • risk factors
  • palliative care
  • drug induced
  • high glucose
  • pain management
  • combination therapy
  • health insurance
  • affordable care act